

SEARCH REQUEST FORM

Requestor's Name: Geetie Bansal Serial Number: 09/177,843
Date: 12/13/99 Phone: 305-3955 Art Unit: 1642

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search Seq ID # 2 and # 1

Thanks

Please search as part of bigger molecule and as a short peptide.

RECEIVED

DEC 14 1999

COMM/CHIEF (STIC)

20 prep

STAFF USE ONLY

Date completed: 12/28/99
Searcher: Toby Port
Terminal time: 10
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
☒ N.A. Sequence
☒ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
mp IG
____ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
____ Other

WIREH

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Thu Dec 23 10:06:56 1999; Maspar time 3.26 Seconds
39.154 Million cell updates/sec
Tabular output not generated.

Title: >US-09-177-843-1
Description: (1-6) from US09177843.pep
Perfect Score: 41
Sequence: 1 GRGDSP 6
Scoring table: PAM 150
Gap 15

Searched: 170751 seqs, 21266508 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-geneseq35
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
14:part14 15:part15 16:part16 17:part17 18:part18
19:part19 20:part20 21:part21 22:part22 23:part23
24:part24 25:part25 26:part26 27:part27 28:part28
29:part29 30:part30 31:part31 32:part32 33:part33
34:part34 35:part35 36:part36 37:part37 38:part38
39:part39

Statistics: Mean 13.672; Variance 32.125; scale 0.426

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description	Pred. No.
1	41	100.0	6 39	W86167	Peptide used in gel c	6.60e+01
2	41	100.0	6 18	R99889	RGD-contg. synthetic	6.60e+01
3	41	100.0	6 5	R25425	Peptide deriv. contg.	6.60e+01
4	41	100.0	6 2	R24212	Fragment of tenascin-	6.60e+01
5	41	100.0	6 17	R89570	RGD-containing sequen	6.60e+01
6	41	100.0	6 17	R92740	RGD-containing sequen	6.60e+01
7	41	100.0	6 6	R29158	PEG-contg. peptide de	6.60e+01
8	41	100.0	6 8	R44046	RGD peptide derivativ	6.60e+01
9	41	100.0	6 7	R33465	Propene-amide deriv.	6.60e+01
10	41	100.0	6 35	W71248	Peptide sequence of t	6.60e+01
11	41	100.0	6 35	W79658	Cyclo(1,6)-Gly-Arg-Gl	6.60e+01
12	41	100.0	7 39	W86169	Peptide used in gel c	6.60e+01
13	41	100.0	7 2	R11505	Cell attachment promo	6.60e+01
14	41	100.0	7 10	R55365	Peptide for use in an	6.60e+01
15	41	100.0	7 20	W03092	Cell attachment pepti	6.60e+01
16	41	100.0	7 9	R46231	Cell adhesion peptide	6.60e+01

17	41	100.0	8 36	W66823	Peptide useful for al	6.60e+01
18	41	100.0 <th>8 16</th> <th>R98332</th> <td>RGD cyclic peptide, T</td> <td>6.60e+01</td>	8 16	R98332	RGD cyclic peptide, T	6.60e+01
19	41	100.0 <td>10 37</td> <td>W68564</td> <td>Cyclic RGD peptide #1</td> <td>6.60e+01</td>	10 37	W68564	Cyclic RGD peptide #1	6.60e+01
20	41	100.0 <td>10 36</td> <td>W68860</td> <td>Peptide useful for al</td> <td>6.60e+01</td>	10 36	W68860	Peptide useful for al	6.60e+01
21	41	100.0 <td>10 4</td> <td>R21012</td> <td>Cyclised integrin rec</td> <td>6.60e+01</td>	10 4	R21012	Cyclised integrin rec	6.60e+01
22	41	100.0 <td>10 19</td> <td>W07433</td> <td>Synthetic, weak, tumo</td> <td>6.60e+01</td>	10 19	W07433	Synthetic, weak, tumo	6.60e+01
23	41	100.0 <td>10 1</td> <td>R05989</td> <td>Cell attachment promo</td> <td>6.60e+01</td>	10 1	R05989	Cell attachment promo	6.60e+01
24	41	100.0 <td>12 19</td> <td>W01134</td> <td>RGD peptide 5 for gll</td> <td>6.60e+01</td>	12 19	W01134	RGD peptide 5 for gll	6.60e+01
25	41	100.0 <td>20 38</td> <td>W81846</td> <td>Fibronectin-like pept</td> <td>6.60e+01</td>	20 38	W81846	Fibronectin-like pept	6.60e+01
26	41	100.0 <td>26 19</td> <td>R95102</td> <td>Fibronectin, FCB port</td> <td>6.60e+01</td>	26 19	R95102	Fibronectin, FCB port	6.60e+01
27	41	100.0 <td>26 31</td> <td>W53511</td> <td>Fibronectin antigen.</td> <td>6.60e+01</td>	26 31	W53511	Fibronectin antigen.	6.60e+01
28	41	100.0 <td>29 3</td> <td>P61391</td> <td>Synthetic fragment of</td> <td>6.60e+01</td>	29 3	P61391	Synthetic fragment of	6.60e+01
29	41	100.0 <td>43 12</td> <td>R65898</td> <td>ACRGD-NLS-1-Sp-35 pep</td> <td>6.60e+01</td>	43 12	R65898	ACRGD-NLS-1-Sp-35 pep	6.60e+01
30	41	100.0 <td>44 12</td> <td>R65890</td> <td>Nucleic acid transfer</td> <td>6.60e+01</td>	44 12	R65890	Nucleic acid transfer	6.60e+01
31	41	100.0 <td>71 1</td> <td>R05300</td> <td>SLPIII (silk-fibroin</td> <td>6.60e+01</td>	71 1	R05300	SLPIII (silk-fibroin	6.60e+01
32	41	100.0 <td>72 19</td> <td>R95106</td> <td>Fibronectin cell bind</td> <td>6.60e+01</td>	72 19	R95106	Fibronectin cell bind	6.60e+01
33	41	100.0 <td>111 7</td> <td>R35685</td> <td>Tryptophan aporepress</td> <td>6.60e+01</td>	111 7	R35685	Tryptophan aporepress	6.60e+01
34	41	100.0 <td>146 19</td> <td>R95140</td> <td>Silk like protein (SL</td> <td>6.60e+01</td>	146 19	R95140	Silk like protein (SL	6.60e+01
35	41	100.0 <td>163 8</td> <td>R44152</td> <td>TNF RGD mutein #8.</td> <td>6.60e+01</td>	163 8	R44152	TNF RGD mutein #8.	6.60e+01
36	41	100.0 <td>171 1</td> <td>P82607</td> <td>Fusion protein derive</td> <td>6.60e+01</td>	171 1	P82607	Fusion protein derive	6.60e+01
37	41	100.0 <td>176 1</td> <td>P82608</td> <td>Fusion protein derive</td> <td>6.60e+01</td>	176 1	P82608	Fusion protein derive	6.60e+01
38	41	100.0 <td>258 11</td> <td>R60343</td> <td>Fibronectin receptor</td> <td>6.60e+01</td>	258 11	R60343	Fibronectin receptor	6.60e+01
39	41	100.0 <td>274 7</td> <td>R34590</td> <td>Fibronectin domain #4</td> <td>6.60e+01</td>	274 7	R34590	Fibronectin domain #4	6.60e+01
40	41	100.0 <td>432 25</td> <td>W33339</td> <td>Human fibroblast grow</td> <td>6.60e+01</td>	432 25	W33339	Human fibroblast grow	6.60e+01
41	41	100.0 <td>472 25</td> <td>W33346</td> <td>Oligopeptide CHV-181.</td> <td>6.60e+01</td>	472 25	W33346	Oligopeptide CHV-181.	6.60e+01
42	41	100.0 <td>491 7</td> <td>R37614</td> <td>Sequence of selected</td> <td>6.60e+01</td>	491 7	R37614	Sequence of selected	6.60e+01
43	41	100.0 <td>695 31</td> <td>W53526</td> <td>Amino acid sequence o</td> <td>6.60e+01</td>	695 31	W53526	Amino acid sequence o	6.60e+01
44	41	100.0 <td>1038 19</td> <td>R95107</td> <td>Fibronectin cell bind</td> <td>6.60e+01</td>	1038 19	R95107	Fibronectin cell bind	6.60e+01
45	41	100.0 <td>1381 2</td> <td>R08032</td> <td>Human Serum Albumin a</td> <td>6.60e+01</td>	1381 2	R08032	Human Serum Albumin a	6.60e+01

ALIGNMENTS

RESULT 1

ID W86167 standard; peptide; 6 AA.
AC W86167;
DT 04-MAR-1999 (first entry)
DE Peptide used in gel contraction assays.
KW Wound contraction; reduction; inhibition; tissue regeneration; scar;
KW wound; joint motion; body deformation; gel contraction.
OS Synthetic.
PN US5851994-A.
PD 22-DEC-1998; 473025.
PF 06-JUN-1995; US-473025.
PR 28-APR-1994; US-234979.
PA (LJOL-) LA JOLLA CANCER RES FOUND.
PI Polarek J, Schreiber R;
DR WPI; 99-080478/07.
PT Inhibition of wound contraction - with peptide derivatives rich in basic amino acids
PS Example 2; Column 13; 16pp; English.
CC The invention provides methods for reduction or inhibition of wound contraction that comprises administration of a peptide having more than 3 consecutive basic amino acid residues. Alternatively, the peptide contains the amino acid sequence Arg-Gly-Asp and a basic amino acid sequence, or the peptide comprises 6-30 amino acids in which at least 4 out of a sequence of 6 consecutive amino acids are basic amino acids.
CC The method is used to allow normal tissue regeneration without excessive scar formation which, in the case of large wounds, can result in loss of joint motion or major body deformation. This peptide is used in gel contraction assays along with the claimed peptides (W86170-83) to determine the activity of a peptide to reduce or inhibit gel contraction.
SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 39; Length 6;

Best Local Similarity 100.0%; Pred. No. 6.60e+01;

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6

Qy 1 GRGDSP 6

RESULT 2
 ID R99889 standard; peptide; 6 AA.
 AC R99889;
 DT 05-NOV-1996 (first entry)
 DE RGD-contg. synthetic peptide ligand.
 KW fibrinogen; blood clotting; GPIIb-IIIa receptor; binding; complex;
 KW epitope; exposed; monoclonal antibody.
 OS Synthetic.
 PN US5470738-A.
 PD 28-NOV-1995.
 PF 08-JUL-1987; 070953.
 PR 08-JUL-1987; US-070953.
 PR 31-MAR-1988; US-175342.
 PR 05-OCT-1989; US-417565.
 PR 04-OCT-1993; US-131320.
 PA (SCRI) SCRIPPS RES INST.
 PI Frelinger AL, Ginsberg MH, Plow EF;
 DR WPI: 96-019874/02.
 PT Monoclonal antibodies specific for ligand-bound GPIIb-IIIa receptor
 PT - useful for detection of clotting disorders and thrombi
 PS Example 1; Column 20; 20pp; English.
 CC Monoclonal antibodies specific for a ligand-induced binding site on
 CC GPIIb, esp. one induced in a platelet-associated GPIIb-IIIa/fibrinogen
 CC complex are claimed. The MAb binds an epitope exposed upon binding of
 CC the ligand and receptor. The epitope is not present on non-bound ligand
 CC or receptor. The MABs are useful to prevent blood clotting and in
 CC diagnostics. The present sequence is a synthetic RGD-contg. peptide
 CC ligand.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 18; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 3
 ID R25425 standard; peptide; 6 AA.
 AC R25425;
 DT 06-JAN-1993 (first entry)
 DE Peptide deriv. contg. RGD motif.
 KW Phosphodiester; liposomes; micelles; fibronectin; cell adhesion;
 KW targeting; tumour metastasis; agglutination; platelets; lymphocytes.
 OS Synthetic.
 PN J04164095-A.
 PD 09-JUN-1992.
 PF 26-OCT-1990; 289490.
 PR 26-OCT-1990; JP-289490.
 PA (FUJF) FUJI PHOTO FILM CO LTD.
 DR WPI: 92-239950/29.
 PT New peptide contg. arginine-glycine-aspartic acid sequence -
 PT useful in prepn. of liposome or micelles used to suppress tumour
 PT metastasis, since sequence is activation site of fibronectin
 PS Example 1; Page 4; 9pp; Japanese.
 CC The peptide is part of a phosphodiester bond which also comprises a
 CC hydrophobic organic gp. e.g. an isoprenoid or glycerolipid. The
 CC new derivs. of the peptide contg. the Arg-Gly-Asp sequence are
 CC useful for the prepn. of liposomes or micelles contg. the RGD
 CC sequence. The RGD sequence is an activation site of fibronectin
 CC which is a cell adhesion mol. The liposomes are useful for the
 CC suppression of tumour metastasis. The liposomes are useful for the
 CC activation of lymphocytes. They are useful for targeting anti-
 CC tumour drugs onto tumours.
 CC See also R25426.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 5; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 4
 ID R24212 standard; Protein; 6 AA.
 AC R24212;
 DT 18-NOV-1992 (first entry)
 DE Fragment of tenascin-related peptide.
 KW Tenascin; related peptide; cell attachment; antibody; angiogenesis;
 KW tumour metastasis; solid matrix; prosthetic device; vascular graft;
 KW percutaneous device.
 PN WO9207872-A.
 PD 14-MAY-1992.
 PF 29-OCT-1991; U08018.
 PR 29-OCT-1990; US-605920.
 PR 30-OCT-1990; US-605667.
 PA (CALB-) CALIFORNIA INST BIOLOGICAL RES.
 PI Bourdon MA;
 DR WPI: 92-183625/22.
 PT New tenascin-related peptides - modulate cell attachment to
 PT tenascin, useful in inhibition of tumour metastasis and
 PT angiogenesis
 PS Disclosure; page 8; 60pp; English.
 CC The peptide may form an N- or C-terminal fragment of the generic
 CC peptide of R24192, which is a tenascin-related peptide. This
 CC peptide mimics the ability of tenascin to promote cell attachment.
 CC The peptide and antibodies raised to it can be used to modulate cell
 CC attachment to tenascin, esp. to inhibit tumour metastasis and
 CC angiogenesis. The peptide is pref. attached to a solid matrix, eg
 CC collagen, nitrocellulose, polyester, glass, synthetic resin, long-chain
 CC polysaccharide or synthetic resin fibre. It is esp. operatively linked
 CC to a solid matrix forming a prosthetic device, percutaneous device,
 CC vascular graft, etc. For topical admin. it is formulated into a
 CC lotion, saline, gel, colloid, powder etc.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 2; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 5
 ID R88570 standard; peptide; 6 AA.
 AC R88570;
 DT 04-SEP-1996 (first entry)
 DE RGD-containing sequence, for controlling cell proliferation.
 KW Laminin-derived peptide; bioartificial; regeneration; nerve;
 KW 3-D hydrogel extracellular matrix; proliferation; neurite;
 KW replacement; cartilage; tendon; muscle; bone; skin.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT peptide 2.4
 FT /note= "Claimed core peptide, claim 2"
 PN WO9602286-A1.
 PD 01-FEB-1996.
 PF 20-JUL-1995; U09282.
 PR 20-JUL-1994; US-280646.
 PA (CYTO-) CYTOTHERAPEUTICS INC.
 PI Aebischer P, Bellamkonda RV, Ranieri JP;
 DR WPI: 96-105660/11.
 PT Bio-artificial 3-D hydrogel extracellular matrix comprising hydrogel
 PT derivatised with adhesion molecules - useful for promoting in vivo
 PT regeneration of severed nerves, tissue replacement and cell
 PT manipulation
 PS Claim 42; Page 497; 65pp; English.
 CC The sequences given in R88569-71 are laminin-derived peptides which

CC were used in the bioartificial 3-D hydrogel extracellular matrix
 CC of the invention to control the distribution of cells. These peptides
 CC are particularly useful in promoting cellular proliferation in neurites.
 CC These peptides are used to derivatise the hydrogel. The hydrogel is a
 CC polysaccharide and has a pore radius of > 120 nm, pref. 150 nm. The
 CC hydrogel is useful for promoting in vivo regeneration of a severed
 CC nerve. It may have cells suspended in it and may be used to promote
 CC in vivo replacement of cartilage, tendon, muscle, bone or skin.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 17; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 6
 ID R92740 standard; peptide; 6 AA.

AC R92740;
 DT 03-SEP-1996 (first entry)
 DE RGD-containing sequence, for controlling cell distribution.
 KW Control; distribution; bioartificial organ; BAO; cellular attachment;
 KW neurotransmitter; hormone; cytokine; growth factor; enzyme.
 OS Synthetic.

FH Key Location/Qualifiers
 FT peptide 2..4
 FT /note= "Claimed core peptide"
 PN W09602646-A2.
 PD 01-FEB-1996.
 PF 20-JUL-1995; U09281.
 PR 20-JUL-1994; US-279773.
 PR 09-MAY-1995; US-432698.
 PA (CYTO-) CYTOTHERAPEUTICS INC.
 PI Aebischer P, Cain BM, Doherty EJ, Gentile FT, Hamang JP;
 PI Holland LM, Schinstine M, Shoichet MS, Winn SR;
 DR WPI; 96-105908/11.

PT Controlling distribution of cells in bio-artificial organs - e.g. by
 PT treatment of cells, or growth surfaces, to inhibit proliferation,
 PT promote differentiation or modulate adhesion, for in vivo prodn. of
 PT hormones, neuro-transmitter(s) etc
 PS Claim 22; Page 70; 84pp; English.
 CC The sequences given in R92739-41 are peptides which were used in the
 CC method of the invention to control the distribution of cells within
 CC a bioartificial organ (BAO). These peptides have been particularly
 CC useful in promoting cellular attachment. These peptides are pref.
 CC bound to the membrane of the BAO which is a biocompatible,
 CC permeable jacket. These peptides act to control the distribution
 CC of the core of living cells included in the BAO after in vivo
 CC implantation. BAO are used therapeutically to produce e.g.
 CC neurotransmitters, hormones, cytokines, growth factors, enzymes, etc.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 17; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 7
 ID R29158 standard; peptide; 6 AA.

AC R29158;
 DT 15-APR-1993 (first entry)
 DE PEG-contg. peptide deriv #1 comprising RGD-motif.
 KW Cell adhesion; Polyethylene glycol; fibronectin.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT modified_site 1

FT /note= "acylated by ROCCH2(OCH2CH2)2NOCH2CO-
 FT where R = GRGDSP and n = 1-150"
 FT modified_site 6
 FT /note= "Opt. amidated and if so, R is also
 FT amidated"
 PN J04305597-A.
 PD 28-OCT-1992.
 PF 02-APR-1991; 068669.
 PR 02-APR-1991; JP-068669.
 PA (FUJIF) FUJIFILM PHOTO FILM CO LTD.
 DR WPI; 92-410149/30.
 PT New peptide-contg. polyethylene glycol derivs. - used to inhibit
 PT cancer metastasis or platelet aggregation and as lymphocyte
 PT activators
 PS Example 1; Page 3; 6pp; Japanese.
 CC The polyethylene glycol-contg. peptide derivs. contain the
 CC Arg-Gly-Asp (RGD) motif found in fibronectin. The derivs can be used
 CC as platelet aggregation inhibitors, lymphocyte activators and cancer
 CC metastasis inhibitors. See also R29159 and R33149.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 6; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 QY 1 GRGDSP 6

RESULT 8
 ID R44046 standard; peptide; 6 AA.

AC R44046;
 DT 02-JUN-1994 (first entry)
 DE RGD peptide derivative #4.
 KW Drug; organ transplantation; rejection; immune disorder;
 KW systemic lupus.
 OS Synthetic.

FH Key Location/Qualifiers
 FT modified_site 1
 FT /note= "C13H27CO-Gly"
 FT modified_site 4
 FT /note= "Pro-OH"

PN J05255105-A.
 PD 05-OCT-1993.
 PF 16-MAR-1992; 058460.
 PR 16-MAR-1992; JP-058460.
 PA (FUJIF) FUJIFILM PHOTO FILM CO LTD.
 DR WPI; 93-348360/44.
 PT Immuno-control drug for organ transplant rejection etc. - contains
 PT peptide having arginine, glycine, aspartic acid sequence
 PS Disclosure; Page 3; 11pp; Japanese.
 CC The sequences given in R44043-47 and R53144 represent examples of the
 CC claimed RGD containing peptide of the invention. These peptides all
 CC correspond to the generic formulae:
 CC HO2-(CH2)m-C(O)-([X]-Arg-Gly-Asp-[Y])n-O-CH2CH(OR1)CH2OR2 or
 CC R3-([X]-Arg-Gly-Asp-[Y])n-Z
 CC [X], [Y] = amino acid or peptide residues;
 CC m = 1-5;
 CC n = 1-5;
 CC R1, R2 = H or 8-24C acyl or alkyl;
 CC R3 = 6-24C acyl;
 CC Z = hydroxyl or amino.

CC These peptides form the active part of drugs which are used for the
 CC control of organ transplantation rejection or immune disorders such
 CC as systemic lupus.
 SQ Sequence 6 AA;

Query Match 100.0%; Score 41; DB 8; Length 6;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6

PI Polarek J, Schreiber R;
 DR WPI: 99-080478/07.
 PT Inhibition of wound contraction - with peptide derivatives rich in
 PS basic amino acids
 CC Example 2; Column 13; 16pp; English.
 CC The invention provides methods for reduction or inhibition of wound
 CC contraction that comprises administration of a peptide having more than
 CC 3 consecutive basic amino acid residues. Alternatively, the peptide
 CC contains the amino acid sequence Arg-Gly-Asp and a basic amino acid
 CC sequence, or the peptide comprises 6-30 amino acids in which at least
 CC 4 out of a sequence of 6 consecutive amino acids are basic amino acids.
 CC The method is used to allow normal tissue regeneration without excessive
 CC scar formation which, in the case of large wounds, can result in loss of
 CC joint motion or major body deformation. This peptide is used in gel
 CC contraction assays along with the claimed peptides (W86170-83) to
 CC determine the activity of a peptide to reduce or inhibit gel contraction.
 SQ Sequence 7 AA;

Query Match 100.0%; Score 41; DB 39; Length 7;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 |||||
 QY 1 GRGDSP 6

RESULT 13
 ID R11505 standard; peptide; 7 AA.
 AC R11505;
 DT 12-JUN-1991 (first entry)
 DE Cell attachment promoting peptide.
 KW Fibrin; aggregation.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT active.site 2..4
 PN US4988621.A.
 PD 29-JAN-1991.
 PF 10-DEC-1987; 131130.
 PR 24-MAY-1985; US-738078.
 PR 10-DEC-1987; US-131130.
 PA (JOLL-) LA JOLLA CANCER FOU
 PI Ruoslanti EI, Hayman EG, Pierschbacher MD;
 DR WPI: 91-116404/16.
 PT Peptide(s) contg. arginine-glycine-aspartic acid sequence - used
 PT to prevent and reverse cell attachment or to promote cell
 PT aggregation.
 PS Disclosure; Page 8; 12pp; English.
 CC The peptide, or shorter versions contg. the RGD active site from
 CC fibronectin, can be used to prevent and reverse attachment of cells
 CC to substrates. This can be used in cell prodn., fermentation, cell
 CC line prepn., cell matrix prodn., diagnostics and therapy. The
 CC peptide can be used for eg mobilisation of bone marrow cells;
 CC prevention and reversal of attachment of disseminated tumour cells
 CC locally such as in the case of an operation performed in the peri-
 CC toneal cavity, to prevent adhesions and scar formations locally as
 CC in the case of eye operations, for prophylactic inhibition of E. coli
 CC binding to epithelial cells of the urinary tract or intestine,
 CC diagnosis and treatment of E. coli related infections, and
 CC identification of various pathogenic bacterial strains. The
 CC peptide is pref. prepd. by solid phase synthesis.
 CC See also R11506.
 SQ Sequence 7 AA;

Query Match 100.0%; Score 41; DB 2; Length 7;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 |||||
 QY 1 GRGDSP 6

RESULT 14
 ID R53365 standard; peptide; 7 AA.
 AC R53365;
 DT 28-JAN-1995 (first entry)
 DE Peptide for use in an immunoassay system for HLA antibodies.
 KW Human platelet antigen; glycoprotein; GPIIb; GPIIa; diagnostic;
 KW alloimmune thrombocytopaenia; post-transfusion purpura.
 OS Synthetic.
 PN WO9411740-A.
 PD 26-MAY-1994.
 PF 08-NOV-1993; G02297.
 PR 07-NOV-1992; GB-023390.
 PA (COMM-) COMMON SERVICES AGENCY.
 PI Bessos H, Murphy WG;
 DR WPI: 94-183676/22.
 PT Immunoassay for antibodies against human platelet antigen - uses
 PT substrate coated with genotyped glyco:proteins GPIIb or GPIIa
 PT suitable for large scale screening
 PS Disclosure; Page 17; 28pp; English.
 CC The peptide is used for affinity purification of GPIIb or GPIIa
 CC The recovered protein eluted with a soln.
 CC contg. an RGD peptide may be used in an immunoassay to detect
 CC antibodies to human platelet antigen (HLA) 1 or 3 Such antibodies
 CC are involved in neonatal alloimmune thrombocytopaenia and post-
 CC transfusional purpura.
 SQ Sequence 7 AA;

Query Match 100.0%; Score 41; DB 10; Length 7;
 Best Local Similarity 100.0%; Pred. No. 6.60e+01;
 Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6
 |||||
 QY 1 GRGDSP 6

RESULT 15
 ID W09092 standard; peptide; 7 AA.
 AC W09092;
 DT 05-MAR-1997 (first entry)
 DE Cell attachment peptide, used in a cell growth substrate.
 KW Cell attachment protein; CAP; cell attachment peptide;
 KW adhesion peptide; dialdehyde starch; cell growth; in vitro.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT modified_site 1
 FT /note= "peptide may be bound to aldehydic groups
 FT on the coated base material (see comments)
 FT via the free alpha-amino group"
 FT modified_site 7
 FT /note= "peptide may be bound to aldehydic groups
 FT on the coated base material (see comments)
 FT via the free side-chain epsilon-amino group"

US5563215-A.
 PN 08-OCT-1996.
 PD 05-NOV-1992; 972327.
 PR 05-NOV-1992; US-972327.
 PR 21-JAN-1994; US-184666.
 PA (CORG) CORNING INC.
 PI Bryhan MD, Hersh LS, Smith FM;
 DR WPI: 96-464201/46.
 PT A cell growth substrate contg. di:aldehyde starch attached to its
 PT surface - useful for growing large numbers of cells for medical
 PT testing and research
 PS Claim 2; Column 12; 20pp; English.
 CC A substrate for growing cells comprising (a) a polymeric base material
 CC selected from polystyrene, polypropylene, polyethylene terephthalate,
 CC polyallomer, cellulose acetate and polymethylpentene; (b) a coating,
 CC on the surface of the base material, containing dialdehyde starch
 CC and (c) a cell attachment peptide (cap) coupled to the coating
 CC Preferred cap sequences are Gly-Arg-Gly-Asp-Ser-Pro-Lys (i.e. the
 CC present sequence), Lys-Gly, Gly-Gly-Tyr-Arg and Arg-Lys-Asp-Val-Tyr.
 CC Large numbers of cells can be grown on the substrate.

SQ Sequence 7 AA;

Query Match 100.0%; Score 41; DB 20; Length 7;
Best Local Similarity 100.0%; Pred. No. 6.60e+01;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 grgdsp 6

|||||

QY 1 GRGDSP 6

Search completed: Thu Dec 23 10:07:16 1999
Job time : 20 secs.